ACHIEVE LIFE SCIENCES INC
ACHVNASDAQTrading Snapshot
- Day Range
- $7.62 – $7.80
- 52-Week Range
- $2.62 – $8.64
- Volume
- $2.84B
- Avg Volume
- $2.57B
- Shares Outstanding
- 102.7M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $138M
- Last Q Revenue
- $33M
- P/E Ratio
- -5.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.22
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +54.4%
Why Investors Own ACHV
- ✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ACHIEVE LIFE SCIENCES INC
ACHV
StockOtter · stockotter.spaceAbout ACHIEVE LIFE SCIENCES INC
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercializatio
Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade)
Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. ACHV's FDA setback was manufacturing-related, not efficacy or safety, with two successful Phase 3 t
Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis
Achieve Life Sciences is navigating a manufacturing reset for cytisinicline following a Complete Response Letter citing facility compliance, not efficacy or safety concerns. I remain bullish on ACHV, contingent on resolv
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Consensus Rating of “Buy” from Brokerages
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) has received a consensus rating of "Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has
Frazier Life Sciences Management L.P. Buys New Stake in Achieve Life Sciences, Inc. $ACHV
Frazier Life Sciences Management L.P. purchased a new position in Achieve Life Sciences, Inc. (NASDAQ: ACHV) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and E
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercializatio